CEPI awards >25 million Euros for LARISSA II

PIKADO BV is proud to announce the successful funding of the next stage of clinical trial of LARISSA vaccine against Rift Valley Fever by CEPI. PIKADO BV assisted with the preparation of both LARISSA I and LARISSA II proposals and is grateful to have been part of this amazing effort to bring an innovative attenuated vaccine against Rift Valley fever to the forefront of clinical research!

Read here the press release of leading institution Wageningen University and Research: https://www.wur.nl/en/research-results/research-institutes/bioveterinary-research/show-bvr/wbvr-awarded-with-25-million-cepi-grant-for-rift-valley-fever-vaccine-research.htm